Trial · NCT07885384
Fruquintinib Combined With Capecitabine as Adjuvant Extended Therapy After R0 Resection and Perioperative Chemotherapy in Patients With Liver-Only Metastatic Colorectal Cancer
NCT07885384, Phase 3, Not yet recruiting, West China Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Fruquintinib Combined With Capecitabine as Adjuvant Extended Therapy After R0 Resection and Perioperative Chemotherapy in Patients With Liver-Only Metastatic Colorectal Cancer. Trials, record NCT07885384. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07885384
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Fruquintinib Combined With Capecitabine as Adjuvant Extended Therapy After R0 Resection and Perioperative Chemotherapy in Patients With Liver-Only Metastatic Colorectal Cancer
- NCT number
- NCT07885384
- Status
- Not yet recruiting
- Phases
- Phase 3
- Enrollment
- 140 participants, estimated
- Lead sponsor
- West China Hospital
- Conditions
- Colorectal Cancer
- Interventions
- Fruquintinib Combined With Capecitabine, Follow-up observation
- First posted
- 2026-10-21
- Last updated
- 2026-10-21
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | DFS1 | From the date of randomization until the date of first documented loco-regional recurrence, distant metastasis (assessed by imaging, CT/MRI) or death from any cause, whichever occurs first, assessed up to 100 months. | Disease-free survival 1(DFS1), defined as the time from randomization until the first occurrence of loco-regional recurrence or distant metastasis (assessed by imaging, CT/MRI) or death from any cause. |
| Secondary | DFS2 | From the date of hepatic R0 surgery until the date of first documented tumor recurrence, metastasis (confirmed by imaging, CT/MRI) or death from any cause, whichever occurs first, assessed up to 100 months. | Disease-free survival 2 (DFS2), defined as the time from the date of hepatic R0 surgery until the first occurrence of tumor recurrence, metastasis (confirmed by imaging, CT/MRI) or death from any cause. |
| Secondary | OS | From the date of randomization until the date of death from any cause, whichever occurs first, assessed by telephone every 6 months, up to 100 months. | Overall survival (OS), defined as the time from the date of randomization until death from any cause, assessed by telephone every 6 months, with a maximum follow-up of 100 months after R0 resection. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07885384
GET https://conductscience.org/api/trials/v1/NCT07885384/registered